Skip to main content
Top
Published in:

01-06-2025 | REVIEW

Metal-modulated T cell antitumor immunity and emerging metalloimmunotherapy

Authors: Peiyun Liao, Ying Zhou, Yingqi Qiu, Rong Hu, Hongyan Li, Hongzhe Sun, Yuhua Li

Published in: Cancer and Metastasis Reviews | Issue 2/2025

Login to get access

Abstract

In recent years, increasing evidence has shown that metals play important roles in both innate and adaptive immunity. An emerging concept of metalloimmunotherapy has been proposed, which may accelerate the development of immunotherapy for cancers. Here, we discuss how metals affect T cell function through different signaling pathways. Metals impact the fate of T cells, including their activation, proliferation, cytotoxicity, and differentiation. Most importantly, metals also participate in mitochondrial operation by regulating energy production and reactive oxygen species homeostasis in T cells. We also identified the metal-based mutual effects between tumor cells and T cells in the tumor microenvironment. Overall, the antitumor effect of T cells can be improved by targeting metal metabolism and metalloimmunotherapy, which will be a step forward in the treatment of cancers. 
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Metal-modulated T cell antitumor immunity and emerging metalloimmunotherapy
Authors
Peiyun Liao
Ying Zhou
Yingqi Qiu
Rong Hu
Hongyan Li
Hongzhe Sun
Yuhua Li
Publication date
01-06-2025
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 2/2025
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-025-10266-2

ASCO 2025 Annual Meeting

Keep up to date with the latest in oncology research with our ASCO 2025 hub page, featuring official videos, breaking news, and more.

Read more

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more